文献速递皮肤肿瘤

ARID2缺陷与黑色素瘤免疫检查点阻断疗效相关

ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
PubMed 文献 · J Invest Dermatol · 2020-12-15

本研究探讨ARID2作为肿瘤免疫调节因子的作用,发现ARID2敲除使黑色素瘤对免疫检查点抑制剂敏感。抗PD-L1治疗抑制ARID2敲除黑色素瘤小鼠的肿瘤生长,伴随细胞毒性CD8+ T细胞浸润增加。ARID2缺陷上调STAT1,进而增加CXCL9、CXCL10和CCL5等T细胞趋化因子表达。

要点

  • ARID2敲除使黑色素瘤对免疫检查点抑制剂敏感
  • 抗PD-L1治疗抑制ARID2敲除肿瘤生长并增加CD8+ T细胞浸润
  • ARID2缺陷上调STAT1并增加T细胞趋化因子表达

核心结论

  • ARID2是免疫调节因子,可能是预测黑色素瘤患者免疫检查点抑制剂疗效的潜在生物标志物。

研究设计与样本

  • 基于小鼠黑色素瘤细胞ARID2敲除模型的实验研究。

主要发现

  • 抗PD-L1治疗限制ARID2敲除黑色素瘤小鼠的肿瘤生长,与细胞毒性CD8+ T细胞浸润增加相关。
  • ARID2缺陷导致STAT1上调,进而增加CXCL9、CXCL10和CCL5等T细胞趋化因子的表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The SWI/SNF chromatin remodeler family includes the BAF and PBAF complexes. ARID2, encoding a PBAF complex subunit, is frequently mutated in melanoma independently of BRAF/RAS mutations. Emerging evidence shows that SWI/SNF complexes regulate tumor immunity; for instance, the loss of PBRM1, another PBAF complex subunit, enhances susceptibility to immune checkpoint inhibitors in melanoma. Notably, ARID2 mutations are more frequent in melanoma than PBRM1 mutations. However, the role of ARID2 as a modulator of tumor immunity remains unclear. In this study, we show that ARID2 knockout sensitizes melanoma to immune checkpoint inhibitors. Anti‒PD-L1 treatment restricts tumor growth in mice bearing ARID2-knockout melanoma cells, correlating with an increase in the infiltration of cytotoxic CD8+ T cells. Furthermore, ARID2 deficiency leads to signal transducer and activator of transcription 1 upregulation, which subsequently causes increased expression of T-cell‒attracting chemokines such as CXCL9, CXCL10, and CCL5. These results demonstrate that ARID2 is an immunomodulator and a potential biomarker that indicates immune checkpoint inhibitor effectiveness in patients with melanoma.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Fukumoto T, Lin J, Fatkhutdinov N, et al. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. J Invest Dermatol. 2020. PMID: 33333124. doi:10.1016/j.jid.2020.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。